Orthocell Ltd has released a press release.
Successful CelGro US Bone Repair Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Orthocell
- US Nerve Repair Study Design Meets FDA Requirements
- SPP Offer Document and Terms And Conditions
- Placement and Share Purchase Plan
- CelGro Nerve Regeneration Results in Quadriplegic Patients
- Successful CelGro Tendon Regeneration Trial
Later from Orthocell
- CelGro US 510(k) Submission Completed
- Orthocells Ortho-ATI Shows 87.5% Success Rate
- CelGro Nerve Repair AUS Regulatory Application Submitted
- CelGro Bone Regeneration in Dental & Orthopedic Applications
- Positive Results in CelGro Nerve Repair Study
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell